Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review)
- Authors:
- Mei Hong Zhang
- Hong Tao Man
- Xiao Dan Zhao
- Ni Dong
- Shi Liang Ma
-
Affiliations: College of Biological Science and Biotechnology, Shenyang Agricultural University, Shenyang, Liaoning 110866, P.R. China - Published online on: October 25, 2013 https://doi.org/10.3892/br.2013.187
- Pages: 41-52
This article is mentioned in:
Abstract
 |
 |
|
Pedraza V, Gomez-Capilla JA, Escaramis G, et al: Gene expression signatures in breast cancer distinguish phenotype characteristics, histologic subtypes, and tumor invasiveness. Cancer. 116:486–496. 2010. View Article : Google Scholar | |
|
Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Bánkfalv A, Ludwig A, De-Hesselle B, Buerger H, Buchwalow IB and Boecker W: Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases. Mod Pathol. 17:1051–1061. 2004.PubMed/NCBI | |
|
Prat A and Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol. 5:5–23. 2011. View Article : Google Scholar | |
|
van’t Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530–536. 2002.PubMed/NCBI | |
|
Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 100:10393–10398. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Chung CH, Bernard PS and Perou CM: Molecular portraits and the family tree of cancer. Nat Genet. 32:533–540. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Liu N, Yu Q, Liu TJ, et al: P-cadherin expression and basal-like subtype in breast cancers. Med Oncol. 29:2606–2612. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI | |
|
Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Onitilo AA, Engel JM, Greenlee RT and Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Herschkowitz JI, Simin K, Weigman VJ, et al: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8:R762007. View Article : Google Scholar : PubMed/NCBI | |
|
Creighton CJ, Li X, Landis M, et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar | |
|
Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar | |
|
Fountzilas G, Dafni U, Bobos M, et al: Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS One. 7:e379462012. View Article : Google Scholar | |
|
Hannemann J, Kristel P, van Tinteren H, et al: Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer. 95:1334–1341. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B and Senn HJ: Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hoch RV, Thompson DA, Baker RJ and Weigel RJ: GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer. 84:122–128. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Jordan VC, Wolf MF, Mirecki DM, Whitford DA and Welshons WV: Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. Crit Rev Clin Lab Sci. 26:97–152. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 7:962006. View Article : Google Scholar : PubMed/NCBI | |
|
Badve S, Turbin D, Thorat MA, et al: FOXA1 expression in breast cancer - correlation with luminal subtype A and survival. Clin Cancer Res. 13:4415–4421. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Oh DS, Troester MA, Usary J, et al: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 24:1656–1664. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Smid M, Wang Y, Zhang Y, et al: Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68:3108–3114. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
van de Vijver MJ, He YD, van’t Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 347:1999–2009. 2002. | |
|
Lacroix M and Leclercq G: About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. Mol Cell Endocrinol. 219:1–7. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Carroll JS and Brown M: Estrogen receptor target gene: an evolving concept. Mol Endocrinol. 20:1707–1714. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Carroll JS, Liu XS, Brodsky AS, et al: Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 122:33–43. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mehta RJ, Jain RK, Leung S, et al: FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat. 131:881–890. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D and Carroll JS: FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 43:27–33. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fang SH, Chen Y and Weigel RJ: GATA-3 as a marker of hormone response in breast cancer. J Surg Res. 157:290–295. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chou J, Provot S and Werb Z: GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 222:42–49. 2010. | |
|
Mehra R, Varambally S, Ding L, et al: Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 65:11259–11264. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Dolled-Filhart M, Rydén L, Cregger M, et al: Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res. 12:6459–6468. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Asselin-Labat ML, Sutherland KD, Barker H, et al: Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 9:201–209. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dawson SJ, Makretsov N, Blows FM, et al: BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 103:668–675. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ali HR, Dawson SJ, Blows FM, et al: A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol. 226:97–107. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Abdel-Fatah TM, Powe DG, Ball G, et al: Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol. 222:388–399. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Callagy GM, Webber MJ, Pharoah PD and Caldas C: Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 8:1532008. View Article : Google Scholar : PubMed/NCBI | |
|
Kallel-Bayoudh I, Hassen HB, Khabir A, et al: Bcl-2 expression and triple negative profile in breast carcinoma. Med Oncol. 28:S55–S61. 2010. View Article : Google Scholar | |
|
Saghatchian M, Mook S, Pruneri G, et al: Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4–9 positive lymph nodes. Breast. Jan 21–2013.(Epub ahead of print). | |
|
Yokoyama J, Kobayashi T, Nakamura T and Nakajima Y: A case of male breast cancer in which oncotype DX was used to determine the therapeutic strategy. Gan To Kagaku Ryoho. 39:2057–2059. 2012.(In Japanese). | |
|
Morris SR and Carey LA: Molecular profiling in breast cancer. Rev Endocr Metab Disord. 8:185–198. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Endo Y, Toyama T, Takahashi S, et al: miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer. Endocr Relat Cancer. 20:91–102. 2013. | |
|
Prat A, Parker JS, Fan C, et al: Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol. 23:2866–2873. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Swedenborg E, Power KA, Cai W, Pongratz I and Rüegg J: Regulation of estrogen receptor beta activity and implications in health and disease. Cell Mol Life Sci. 66:3873–3894. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
El-Tanani MK and Green CD: Interaction between estradiol and growth factors in the regulation of specific gene expression in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol. 60:269–276. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Osz J, Brelivet Y, Peluso-Iltis C, et al: Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors. Proc Natl Acad Sci USA. 109:E588–E594. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Choi KC and Jeung EB: The biomarker and endocrine disruptors in mammals. J Reprod Dev. 49:337–345. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Chawla A, Repa JJ, Evans RM and Mangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science. 294:1866–1870. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Loi S, Sotiriou C, Haibe-Kains B, et al: Gene expression profiling identifies activated growth factor signaling in poor prognosis (luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics. 2:372009. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HR, Hwang KA, Park MA, Yi BR, Jeung EB and Choi KC: Treatment with bisphenol A and methoxychlor results in the growth of human breast cancer cells and alteration of the expression of cell cycle-related genes, cyclin D1 and p21, via an estrogen receptor-dependent signaling pathway. Int J Mol Med. 29:883–890. 2012. | |
|
Anderson E: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 4:197–201. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hartman J, Strom A and Gustafsson JA: Estrogen receptor beta in breast cancer - diagnostic and therapeutic implications. Steroids. 74:635–641. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 23:7350–7360. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mauri D, Pavlidis N, Polyzos NP and Ioannidis JP: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 98:1285–1291. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 365:60–62. 2005. | |
|
Fox EM, Arteaga CL and Miller TW: Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer. Front Oncol. 2:1452012. | |
|
Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 9:631–643. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
No authors listed. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 351:1451–1467. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Harris TJ and McCormick F: The molecular pathology of cancer. Nat Rev Clin Oncol. 7:251–265. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar | |
|
Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet P and Grenier J: Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer. 83:698–705. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 96:926–935. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Rutanen EM, Pekonen F, Nyman T and Wahlström T: Insulin-like growth factors and their binding proteins in benign and malignant uterine diseases. Growth Regul. 3:74–77. 1993.PubMed/NCBI | |
|
O’Toole SA, Dunn E, Sheppard BL, et al: Oestrogen regulated gene expression in normal and malignant endometrial tissue. Maturitas. 51:187–198. 2005.PubMed/NCBI | |
|
Millar EK, Graham PH, O’Toole SA, et al: Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 27:4701–4708. 2009. View Article : Google Scholar | |
|
Miller KD, Burstein HJ, Elias AD, et al: Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol. 23:5632005. | |
|
Coxon A, Bush T, Saffran D, et al: Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res. 15:110–118. 2009. View Article : Google Scholar | |
|
Ma CX, Crowder RJ and Ellis MJ: Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids. 76:750–752. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hisamatsu Y, Tokunaga E, Yamashita N, et al: Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 19:1145–1152. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Habashy HO, Rakha EA, Aleskandarany M, et al: FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Res Treat. 129:11–21. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lanari C, Wargon V, Rojas P and Molinolo AA: Antiprogestins in breast cancer treatment: are we ready? Endocr Relat Cancer. 19:R35–R50. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cui X, Schiff R, Arpino G, Osborne CK and Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 23:7721–7735. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Safe S and Kim K: Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol. 77:1–36. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hewitt SC and Korach KS: Estrogen receptors: structure, mechanisms and function. Rev Endocr Metab Disord. 3:193–200. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gohno T, Seino Y, Hanamura T, et al: Individual transcriptional activity of estrogen receptors in primary breast cancer and its clinical significance. Cancer Med. 1:328–337. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Perou CM, Jeffrey SS, van de Rijn M, et al: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 96:9212–9217. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Loi S, Haibe-Kains B, Desmedt C, et al: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 25:1239–1246. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Turner N, Pearson A, Sharpe R, et al: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70:2085–2094. 2010. View Article : Google Scholar | |
|
de Azambuja E, Cardoso F, de Castro GJ Jr, et al: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 96:1504–1513. 2007.PubMed/NCBI | |
|
Tran B and Bedard PL: Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 13:2212011. View Article : Google Scholar : PubMed/NCBI | |
|
Wirapati P, Sotiriou C, Kunkel S, et al: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10:R652008. View Article : Google Scholar : PubMed/NCBI | |
|
Prat A, Ellis MJ and Perou CM: Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 9:48–57. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nielsen TO, Parker JS, Leung S, et al: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 16:5222–5232. 2010. View Article : Google Scholar | |
|
Rakha EA, El-Sayed ME, Reis-Filho JS and Ellis IO: Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology. 52:67–81. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Osborne CK, Neven P, Dirix LY, et al: Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 17:1147–1159. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lønning PE: Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. Ther Adv Med Oncol. 4:127–137. 2012.PubMed/NCBI | |
|
Millar EK, Graham PH, McNeil CM, et al: Prediction of outcome of early ER+breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer. 105:272–280. 2011.PubMed/NCBI | |
|
Jacquemier J, Charafe-Jauffret E, Monville F, et al: Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res. 11:R232009. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita H, Toyama T, Nishio M, et al: p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res. 8:R482006. View Article : Google Scholar : PubMed/NCBI | |
|
Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 63:6523–6531. 2003.PubMed/NCBI | |
|
Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 99:167–170. 2007. View Article : Google Scholar | |
|
Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M and Federico M: Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women. Tumori. 98:743–750. 2012.PubMed/NCBI | |
|
Wertheimer E, Gutierrez-Uzquiza A, Rosemblit C, Lopez-Haber C, Sosa MS and Kazanietz MG: Rac signaling in breast cancer: a tale of GEFs and GAPs. Cell Signal. 24:353–362. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lips EH, Mulder L, Ronde JJ, et al: Neoadjuvant chemotherapy in ER+HER2−breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat. 131:827–836. 2012.PubMed/NCBI | |
|
Creighton CJ, Fu X, Hennessy BT, et al: Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+breast cancer. Breast Cancer Res. 12:R402010. View Article : Google Scholar : PubMed/NCBI | |
|
Osborne CK, Shou J, Massarweh S and Schiff R: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 11:865s–870s. 2005.PubMed/NCBI | |
|
Zhang Y, Su H, Rahimi M, Tochihara R and Tang C: EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer. 125:2021–2028. 2009. View Article : Google Scholar | |
|
Thakkar JP and Mehta DG: A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist. 16:276–285. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Charafe-Jauffret E, Ginestier C, Monville F, et al: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 25:2273–2284. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Katoh M: Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. Expert Rev Anticancer Ther. 10:1375–1379. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sircoulomb F, Nicolas N, Ferrari A, et al: ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med. 3:153–166. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Karn T, Ruckhäberle E, Hanker L, et al: Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat. 130:409–420. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bergamaschi A, Christensen BL and Katzenellenbogen BS: Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis. Breast Cancer Res. 13:R702011.PubMed/NCBI | |
|
Glynn RW, Miller N, Mahon S and Kerin MJ: Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer. Oncol Rep. 28:365–369. 2012.PubMed/NCBI | |
|
Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 360:790–800. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol 3-kinase/AKT- mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem. 276:9817–9824. 2001. | |
|
Law JH, Habibi G, Hu K, et al: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68:10238–10246. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Browne BC, O’Brien N, Duffy MJ, Crown J and O’Donovan N: HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets. 9:419–438. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rodríguez-Pinilla SM, Sarrió D, Honrado E, et al: Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol. 60:1006–1012. 2007.PubMed/NCBI | |
|
Matos I, Dufloth R, Alvarenga M, Zeferino LC and Schmitt F: p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 447:688–694. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG and Weiss SJ: Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic breast cancer 1, early onset (BRCA1) repression. Proc Natl Acad Sci USA. 109:16654–16659. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2:127–137. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kurokawa H, Lenferink AE, Simpson JF, et al: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 60:5887–5894. 2000. | |
|
Moulder SL, Baetz T, Borges V, et al: ARRY-380, a selective HER2 inhibitor: from drug design to clinical evaluation. Mol Cancer Ther. 10:abs. A143. 2011. View Article : Google Scholar | |
|
Nelson JM and Fry DW: Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem. 276:14842–14847. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Rabindran SK, Discafani CM, Rosfjord EC, et al: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64:3958–3965. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lai CJ, Bao R, Tao X, et al: CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 70:3647–3656. 2010. View Article : Google Scholar | |
|
Hickinson DM, Klinowska T, Speake G, et al: AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res. 16:1159–1169. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Haluska P, Carboni JM, TenEyck C, et al: HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther. 7:2589–2598. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Miknis G, Wallace E, Lyssikatos J, et al: ARRY-334543, a potent, orally active small molecule inhibitor of EGFR and ErbB-2. Proc Amer Assoc Cancer Res. 24:abs. 3399. 2005. | |
|
Kalous O, Conklin D, Desai AJ, et al: Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 11:1978–1987. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ishikawa T, Seto M, Banno H, et al: Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem. 54:8030–8050. 2011. | |
|
Powis G, Ihle N and Kirkpatrick DL: Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res. 12:2964–2966. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW and Baselga J: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 3:2099–2106. 1997. | |
|
Wilhelm SM, Dumas J, Adnane L, et al: Regorafenib (BAY 73–4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 129:245–255. 2011. | |
|
Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Falcon BL, Barr S, Gokhale PC, et al: Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 71:1573–1583. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 9:327–337. 2003. | |
|
Hu-Lowe DD, Zou HY, Grazzini ML, et al: Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 14:7272–7283. 2008. View Article : Google Scholar | |
|
Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65:4389–4400. 2005. View Article : Google Scholar | |
|
Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62:4645–4655. 2002.PubMed/NCBI | |
|
Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A and Asada M: Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 14:5459–5465. 2008. View Article : Google Scholar | |
|
Fletcher GC, Brokx RD, Denny TA, et al: ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 10:126–137. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Strumberg D, Schultheis B, Adamietz IA, et al: Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer. 99:1579–1585. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Albert DH, Tapang P, Magoc TJ, et al: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 5:995–1006. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mi YJ, Liang YJ, Huang HB, et al: Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 70:7981–7991. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yakes FM, Chen J, Tan J, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 10:2298–2308. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mordant P, Loriot Y, Leteur C, et al: Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther. 9:358–368. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gendreau SB, Ventura R, Keast P, et al: Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res. 13:3713–3723. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Turner N and Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gavine PR, Mooney L, Kilgour E, et al: AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72:2045–2056. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
García-Echeverría C, Pearson MA, Marti A, et al: In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 5:231–239. 2004.PubMed/NCBI | |
|
Sabbatini P, Rowand JL, Groy A, et al: Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res. 15:3058–3067. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, et al: Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 1:1153–1171. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wen B, Deutsch E, Marangoni E, et al: Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer. 85:2017–2021. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Sabbatini P, Korenchuk S, Rowand JL, et al: GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 8:2811–2820. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW and Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 407:538–541. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Migliaccio A, Castoria G, Di Domenico M, et al: Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J. 19:5406–5417. 2000.PubMed/NCBI | |
|
Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 15:429–440. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yu K, Toral-Barza L, Shi C, Zhang WG and Zask A: Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther. 7:307–315. 2008.PubMed/NCBI | |
|
Smirnova T, Zhou ZN, Flinn RJ, et al: Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 31:706–715. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Knight SD, Adams ND, Burgess JL, et al: Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett. 1:39–43. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mallon R, Hollander I, Feldberg L, et al: Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther. 9:976–984. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sutherlin DP, Bao L, Berry M, et al: Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem. 54:7579–7587. 2011. View Article : Google Scholar | |
|
Venkatesan AM, Dehnhardt CM, Delos Santos E, et al: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem. 53:2636–2645. 2010.PubMed/NCBI | |
|
Rhodes N, Heerding DA, Duckett DR, et al: Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68:2366–2374. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Grimshaw KM, Hunter LJ, Yap TA, et al: AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Mol Cancer Ther. 9:1100–1110. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Meuillet EJ, Zuohe S, Lemos R, et al: Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 9:706–717. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lu CH, Wyszomierski SL, Tseng LM, et al: Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res. 13:5883–5888. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Feldman RI, Wu JM, Polokoff MA, et al: Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 280:19867–19874. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Cully M, You H, Levine AJ and Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shor B, Zhang WG, Toral-Barza L, et al: A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res. 68:2934–2943. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Rivera VM, Squillace RM, Miller D, et al: Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 10:1059–1071. 2011. View Article : Google Scholar | |
|
Yuan J, Mehta PP, Yin MJ, et al: PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 10:2189–2199. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chresta CM, Davies BR, Hickson I, et al: AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70:288–298. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bhagwat SV, Gokhale PC, Crew AP, et al: Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 10:1394–1406. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wallin JJ, Edgar KA, Guan J, et al: GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 10:2426–2436. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yu K, Toral-Barza L, Shi C, et al: Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69:6232–6240. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Guichard SM, Howard Z, Heathcote D, et al: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+breast cancer. Cancer Res. 72:abs. 917. 2012. View Article : Google Scholar | |
|
Liu Q, Thoreen C, Wang J, Sabatini D and Gray NS: mTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strateg. 6:47–55. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hawkins W, Mitchell C, McKinstry R, et al: Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biol Ther. 4:1275–1284. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ohren JF, Chen H, Pavlovsky A, et al: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 11:1192–1197. 2004. View Article : Google Scholar : PubMed/NCBI |
